



NDA 021187/S-028

**SUPPLEMENT APPROVAL**

Organon USA Inc., a subsidiary of Merck & Co., Inc.  
Attention: Shawn Moylan, M.S. Pharm.D.  
Regulatory Liaison, Global Regulatory Affairs  
P.O. Box 1000  
North Wales, PA 19454

Dear Dr. Moylan:

Please refer to your Supplemental New Drug Application (sNDA) dated and received August 10, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring).

This Prior Approval supplemental new drug application provides for changes to the Prescribing Information (PI) for NuvaRing to update the 1) Dosage and Administration Section, subsection, Use with Other Vaginal Products, and 2) Drug Interactions Section, subsection, Effects of Other Drugs on Combined Hormonal Contraceptives (CHCs).



The non-safety labeling changes in (b) (4) were incorporated into the S-028 labeling, which provides for changes to the PI to update the 1) Dosage and Administration Section, subsection Deviations from the Recommended Regimen, 2) Use in Special Populations Section, subsection Pregnancy (in accordance with the Pregnancy and Lactation Labeling Rule), 3) Non-clinical Toxicology Section, subsection Impairment of Fertility and 4) reformatting the Patient Counseling Information Section for consistency with other CHC labeling.

Additionally, changes were made to the Patient Package Insert (PPI) to update the, 1) “How should I use NuvaRing?” Section, 2) “General information about the safe and effective use of NuvaRing” Section, in accordance with changes made to the PI, 3) Instructions for Use Section and 4) minor editorial changes.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Charlene Williamson, Regulatory Project Manager, at (301) 796-1025.

Sincerely,

*{See appended electronic signature page}*

Hylton V. Joffe, M.D., M.M.Sc.  
Director  
Division of Bone, Reproductive and Urologic Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

HYLTON V JOFFE  
05/30/2017